Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-predictable routine of online calls, meetings, and deadlines has, of course, returned. But what can you do? The world, such as it is, keeps spinning. So time to give it a nudge in the right direction. We have the strength to do so thanks to a delicious cup of stimulation. Our choice today is an old standby — hazelnut. Feel free to join us. Meanwhile, here are some tidbits to help you embark on your journey today. We hope the time spent is productive and, as always, remind you to keep us in mind when something saucy crosses your path. …

Biogen (BIIB) reported disappointing results from a late-stage study of its experimental treatment for a rare, genetically defined form of amyotrophic lateral sclerosis, or Lou Gehrig’s disease, STAT writes. The drug failed to slow neurologic and functional decline compared to a placebo. Although the drug showed some improvements on other measures of disease progression, interpreting the secondary results is challenging because the main study goal was not met. Tofersen targets an inherited form of ALS that is diagnosed in about 100 patients each year, just 2% of overall diagnoses. Still, the negative study results are another unfortunate setback for the broader ALS patient community.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment